Preliminary positive immune response data announced from Ph 3 clinical trial FLAMINGO-01 of GLSI-100 April 8, 2025
SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer April 8, 2025
SC Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior PK Compared to IV KEYTRUDA in Pivotal 3475A-D77 Trial April 2, 2025
FAILED TRIAL: Ph 3 ARTISTRY-7 Trial of Nemvaleukin + KEYTRUDA in Patients with Platinum-Resistant Ovarian Cancer did not achieve a statistically significant improvement in OS April 2, 2025
Primary Endpoint Met in Pivotal Ph 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer April 2, 2025
RYBREVANT (amivantamab-vmjw) + LAZCLUZE (lazertinib) outperform osimertinib with a significant OS benefit in patients with EGFR-mutated NSCLC April 2, 2025
In LAURA Ph 3 trial, Tagrisso continues to demonstrate improved OS trend in unresectable, Stage III setting April 2, 2025
75.5% CR at any time in Ph 3 study of cretostimogene monotherapy for high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS) April 2, 2025
Both Prolonged Median OS and Long Tail of Survival in Ph 2a Trial of CAN-2409 in Advanced NSCLC Patients Non-Responsive to ICI Treatment Reported April 2, 2025
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment March 26, 2025
FRUSICA-2 Ph 2/3 Study of Sintilimab and Fruquintinib Combination Met Primary Endpoint in Advanced RCC in China March 26, 2025
SGO 2025: Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer March 26, 2025
Positive Topline Result for TEDOPaM Ph 2 trial of OSE2101 (Tedopi) in Advanced Pancreatic Cancer Announced March 18, 2025
SGO 2025: ELAHERE (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients March 18, 2025
Actimab-A + CLAG-M Trial Results in Patients with R/R AML published in the Journal Leukemia March 18, 2025
JAMA Study suggests that Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression March 18, 2025
SGO 2025: Updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC announced March 18, 2025
SGO 2025: Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer Presented March 18, 2025
SGO 2025: Rinatabart Sesutecan (Rina-S) Shows Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer March 18, 2025
Ph 3 Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab published in The Lancet March 11, 2025
